Business
Moderna Announces COVAX Exercises Option to Purchase 176.5 Million Additional Doses of Moderna’s COVID-19 Vaccine for Low Income Countries in First Half of 2022
More than 210 million doses have now been purchased by COVAX for delivery to low income countries, including 34 million doses that will be delivered in Q4
About this update from Moderna, Inc.
[{"type":"text","content":"\nMore than 210 million doses have now been purchased by COVAX for delivery to low income countries, including 34 million doses that will be delivered in Q4 2021\n\nCOVAX has options to purchase an additional 233 million doses in second half of 2022\n\nDoses provided at lowest tiered price, in keeping with Moderna’s global access principles\n\nModerna has requested authorization of a 50 µg booster dose from global regulators, which could significantly increase doses available to low income countries\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nModerna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Gavi, the Vaccine Alliance has exercised its option to purchase an additional 176.5 million doses of the Moderna COVID-19 vaccine for the COVAX Facility. Of these additional doses, 116.5 million doses are expected to be delivered in the first quarter of 2022 and 60 million doses are expected to be delivered in the second quarter of 2022. All doses are offered at Moderna’s lowest tiered price, in line with the Company’s global access commitments.\n\nCOVAX retains the option to purchase 116.5 million doses for delivery in the third quarter of 2022 and an additional 116.5 million doses for delivery in the fourth quarter of 2022. These doses are in addition to the 34 million doses purchased for delivery in the fourth quarter of 2021.\n\nThe 210 million doses purchased to date by COVAX are 100 µg per dose. Recently, Moderna has requested authorization of a 50 µg dose as a booster from the same vial which would significantly increase the number of usable doses procured by COVAX at no additional cost. The average purchase price across all doses purchased to date is just under $10 per 100 µg dose, equating to less than $5 per 50 µg dose.\n\n“I would like to thank COVAX for their tireless work to deliver our vaccine to low income countries. We support COVAX’s mission to ensure broad, affordable and equitable access to COVID-19 vaccines and this agreement is an important pillar of our access strategy,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We believe our vaccine can play an important role in addressing the needs of low income countries given its combination of high Phase 3 efficacy against COVID-19, strong durability in the real-world evidence, and su...